NEW YORK, Dec. 30, 2010 /PRNewswire-FirstCall/ — InstaCare
Corp. (OTC Bulletin Board:
ISCR), the exclusive distributor of the Shasta Genstrip
diagnostic testing strips, a leading provider of prescription and
non-prescription diagnostics, home testing products for the
chronically ill, as well as leading fulfillment provider of direct
to patient diabetes programs, and a developer of revolutionary cell
phone centric e-health products and technologies, today
announced that the company’s Board of Directors will, during the
month of January 2011, release Guidance for fiscal year 2011.
On January 10, 2011, a preliminary Guidance release will
highlight financial information related to its new at-home
diagnostic product, the Shasta Genstrip.
A more comprehensive Guidance release will be issued on January
24, 2011. A shareholder conference call is also planned following
the January 24 Guidance release. The details of the shareholder
call, including call-in information, will be made available on our
website, www.instacare.net.
Robert Jagunich, Chairman of InstaCare Corp., noted
enthusiastically, “These Guidance releases, to be evaluated by an
independent financial analyst prior to their release, should
communicate the basis of our internal optimism and our confidence
in InstaCare’s business and revenue models. We believe that our
shareholders and the investment community will be impressed with
our financial and marketing plan for 2011 and our strategic long
term vision. InstaCare will be forecasting, for the first time, the
depth and breadth of the financial opportunity that is represented
by our new at-home diagnostic testing product, Shasta
Genstrip.”
For more information about InstaCare Corp. the Shasta Genstrip
or its revolutionary MD@Hand cell phone centric technologies,
please visit the InstaCare web s
‘/>”/>
SOURCE
